Nl-Fr

Bridging Academia and Industry: Road to Enhance Therapy for Ocular Inflammatory Disease – FOIS

View entire scheduleShow Abstracts for this session
Organized by the Foster Ocular Immunology Society (FOIS)
Session
Saturday 9 September 2023, 09:00 - 10:00, Room 2 — B05-06
Moderators
Quan Dong NGUYEN, David CHU, Esen AKPEK
 09:00Welcome and Introduction
09:01Importance of Participation in Clinical Trials at Academic Practices – Significance and Challenges DURRANI K
09:10Programs in IL-17 Inhibitor and JAK-Inhibitor for Uveitis – Similarities and Differences in Approaches to Conducting Clinical Trials SHAH R
09:19Topical Dexamethasone and Topical Laquinimod for Ocular Inflammatory Diseases – Similarities and Differences in Approaches to Conducting Clinical Trials OR C
 09:28PANEL DISCUSSION: Panelists – DURRANI K, HAIM-LANGFORD D, JOHNSON B, OR C, RUBIO R, SEPAH Y, SHAH R, VAHTOLA E
 10:00End of Session

The Panelists 
  • Khayyam DURRANI, MD (University of Connecticut
  • Daphne HAIM-LANGFORD, PhD, Founder and Chief Executive Officer, Tarsier Pharma
  • Brendan JOHNSON, PhD, Senior Vice President, Early Development, Priovant Therapeutics, Inc. (Email: brendan.johnson@priovanttx.com) Christopher OR, MD
  • Roman RUBIO, MD, MBA, Senior Vice President for Clinical Development and Translational Medicine, Alumis, Inc.
  • Yasir J. SEPAH, MBBS, Co-Founder, Ocular Imaging Research and Reading Center (OIRRC) and CREST
  • Rajiv SHAH, MD (Wake Forest University)
  • Erik VAHTOLA, MD, PhD, Chief Medical Officer, Active BioTech